Cancer Research (journal)

November 6, 2014

Immune cell activity and melanoma

The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells.

By VUMC News and Communications
red laser beam
October 1, 2014

Optical imaging in drug therapy screens

A non-invasive imaging tool could test potential cancer therapies quickly to personalize therapy for patients.

By VUMC News and Communications
August 28, 2014

Limiting breast cancer metastasis

Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.

By Brandon Turner
July 31, 2014

New target for breast cancer therapy

The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics.

By Leigh MacMillan
February 7, 2014

New direction for treating lung cancer

Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.

By Leigh MacMillan
December 18, 2013

Targeting tumor “supply lines”

A metabolic enzyme plays a crucial role in vascular development and may be a good target for cancer therapies.

By Leigh MacMillan
December 5, 2013

Predictor of prostate cancer outcomes identified

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread.
By VUMC News and Communications
October 17, 2013

New technique tracks breast cancer subtypes, treatment effectiveness

A group of Vanderbilt researchers has used laser technology and a custom-built multiphoton microscope to distinguish breast cancer subtypes and determine if specific therapies are working against the cancer cells in as little as two days.
By VUMC News and Communications
August 22, 2013

Overcoming resistance in ovarian cancer

The nuclear receptor TR3 contributes to ovarian cancer cell death in response to platinum-based chemotherapy – and may be a good target for overcoming cell resistance to certain treatments.
By Leigh MacMillan
June 10, 2013

Factor’s yin-yang tumor effects

A factor produced by most malignant cells can both promote and inhibit tumor growth – an insight that is critical to using cancer drugs developed to block this factor.
By Leigh MacMillan
September 27, 2012

Target acquired for aggressive tumor

New therapeutic target for angiosarcoma – an aggressive, highly fatal tumor of the blood vessels – identified.
By VUMC News and Communications
1 2